Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data. (PubMed, Blood Rev) - Sep 6, 2026 - "Commonly used TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib, asciminib, and olverembatinib) all have positive and negative impacts on QoL, each of which can be impacted by patient preference and priorities, as well as line of therapy. The inclusion of patient-reported QoL outcomes in clinical trials will be vital to helping physicians understand the patient experience of CML and thereby improve disease management."
HEOR • Journal • Review • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Christopher Hillis; Delphine Rea; Elisabetta Abruzzese; Giora Sharf; Jeffrey H Lipton; Meinolf Suttorp; Qian Jiang; Robert Peter Gale
|